A phase I, open-label, dose-escalation study to assess the safety, tolerability and pharmacokinetics of AZD4877 administered weekly or every two weeks in patients with advanced solid malignancies
Phase of Trial: Phase I
Latest Information Update: 12 May 2009
At a glance
- Drugs AZD 4877 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 23 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jun 2008 The expected completion date for this trial is now 1 Sep 2008, according to ClinicalTrials.gov.
- 30 Jun 2008 Status changed from recruiting to in progress, reported by Clinicaltrials.gov.